Despite advances, there remain gaps in the understanding of and personalized treatment for chronic pain in rheumatology, especially among women.

Upadacitinib demonstrated long-term efficacy for the treatment of ankylosing spondylitis among patients who failed to respond to prior biologic therapy.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

A recent study finds that the prevalence of post-COVID-19 condition was 8.4 percent among U.S. adults in 2023.

Black children are suspected to have experienced child abuse at higher rates than children of other racial and ethnic backgrounds.

A brief outpatient rehabilitation program with a cognitive and behavioral approach is effective for patients with post-COVID-19 condition.

HealthDay News — Substance use among adolescents has continued to hold steady at lowered levels for the fourth year in a row, according to the U.S. National Institutes of Health (NIH)-funded ...

Gestational hypertension, preeclampsia, and eclampsia are associated with an increased risk for neurological outcomes after giving birth.

The FDA has approved Steqeyma® (ustekinumab-stba), a biosimilar to Stelara®, for the treatment of various chronic ...

Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found when comparing healthy controls.

Exposure to TNF inhibitors was linked to a reduced risk for cardiovascular events among patients with AS; the impact of IL-17 inhibitors was less clear.

“These findings suggest that BMI and obesity prevalence in the U.S. decreased in 2023 for the first time in more than a decade,” the authors write. “The most notable decrease was in the South, which ...